Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition

To see complete record on, please visit this link

Id: NCT03237286

Organisation Name: University of Pittsburgh

Overal Status: Active, not recruiting

Start Date: December 1, 2017

Last Update: October 20, 2022

Lead Sponsor: Rebecca Price

Brief Summary: This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training. Three of the primary outcomes listed (fMRI functional connectivity; Implicit Association Test; cognitive flexibility testing) pertain to Aim 1. For Aim 2, one primary clinical outcome (MADRS, a clinician-administered measure of depression severity) pertains to the acute (30-day) phase, while the QIDS (a self-report measure of depression severity) becomes the primary clinical outcome during the 12-month naturalistic follow-up.

  • Depression

Total execution time in seconds: 0.27052998542786